Gynecological cancers are major contributors to the total cancer burden in women. It is estimated that half a million deaths are annually caused worldwide by cancers of the female reproductive react, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.
Ovarian cancers are primarily accountable for the high mortality rate in gynecological cancers, mainly due to a lack of early diagnostic tools and recurrences resulting from chemoresistance. For endometrial cancers, lack of diagnostic tools and chemoresistance are also true and therapeutic options for advanced disease remain scarce. Over the last two decades, some improvements have been seen, specifically in the development of the HPV vaccine which has been paramount for the diminution of the incidence of cervical cancer; however, cervical cancer is still a significant issue in lower income countries where the vaccination plan does not include the HPV vaccine.
Despite current knowledge of the molecular and genetic events behind gynecological cancers, the field still has a lot to improve on, such as the development of new molecular approaches to prevention, screening, diagnosis, and novel targeted therapies.
The management of female reproductive tract tumors is an actual challenge in the oncology field. This collection aims to gather studies about the genetics, epigenetics, transcriptomics, and proteomics of gynecological malignancies which directly contribute towards improved clinical management. This collection will accept manuscripts on, but not limited to, the following research areas:
- Identification of new validated biomarkers in gynecological malignancies
- Molecular pathology methods to improve the diagnosis of gynecological malignancies
- The identification of genetic, epigenetic, transcriptomic, and proteomic alterations in gynecological malignancies
- NGS panels with clinical utility namely those that can be used to identify specific genotypes such as those associated with homologous recombination pathway deficiency
- The identification of novel targets for the treatment of gynecologic malignancies
- Results from laboratory assays and clinical trials using monotherapy or combination approaches with novel targeted therapies or repurposed drugs
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Gynecological cancers are major contributors to the total cancer burden in women. It is estimated that half a million deaths are annually caused worldwide by cancers of the female reproductive react, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.
Ovarian cancers are primarily accountable for the high mortality rate in gynecological cancers, mainly due to a lack of early diagnostic tools and recurrences resulting from chemoresistance. For endometrial cancers, lack of diagnostic tools and chemoresistance are also true and therapeutic options for advanced disease remain scarce. Over the last two decades, some improvements have been seen, specifically in the development of the HPV vaccine which has been paramount for the diminution of the incidence of cervical cancer; however, cervical cancer is still a significant issue in lower income countries where the vaccination plan does not include the HPV vaccine.
Despite current knowledge of the molecular and genetic events behind gynecological cancers, the field still has a lot to improve on, such as the development of new molecular approaches to prevention, screening, diagnosis, and novel targeted therapies.
The management of female reproductive tract tumors is an actual challenge in the oncology field. This collection aims to gather studies about the genetics, epigenetics, transcriptomics, and proteomics of gynecological malignancies which directly contribute towards improved clinical management. This collection will accept manuscripts on, but not limited to, the following research areas:
- Identification of new validated biomarkers in gynecological malignancies
- Molecular pathology methods to improve the diagnosis of gynecological malignancies
- The identification of genetic, epigenetic, transcriptomic, and proteomic alterations in gynecological malignancies
- NGS panels with clinical utility namely those that can be used to identify specific genotypes such as those associated with homologous recombination pathway deficiency
- The identification of novel targets for the treatment of gynecologic malignancies
- Results from laboratory assays and clinical trials using monotherapy or combination approaches with novel targeted therapies or repurposed drugs
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
